Trial Profile
Phase I Clinical Trial of Recombinant Humanized Anti-vegf Monoclonal Antibody Single Vitreous Injection for Safety, Tolerance, PK and Pharmacodynamics in nAMD Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- 09 Nov 2018 New trial record